Fattouh Ramzi, Midence N Gabriela, Arias Katherine, Johnson Jill R, Walker Tina D, Goncharova Susanna, Souza Kailene P, Gregory Richard C, Lonning Scott, Gauldie Jack, Jordana Manel
Department of Pathology and Molecular Medicine, Head, Division of Respiratory Diseases and Allergy, MDCL 4013, McMaster University, 1200 Main Street West, Hamilton, ON, Canada.
Am J Respir Crit Care Med. 2008 Mar 15;177(6):593-603. doi: 10.1164/rccm.200706-958OC. Epub 2008 Jan 3.
It is now believed that both chronic airway inflammation and remodeling contribute significantly to airway dysfunction and clinical symptoms in allergic asthma. Transforming growth factor (TGF)-beta is a powerful regulator of both the tissue repair and inflammatory responses, and numerous experimental and clinical studies suggest that it may play an integral role in the pathogenesis of asthma.
We investigated the role of TGF-beta in the regulation of allergic airway inflammation and remodeling using a mouse model of house dust mite (HDM)-induced chronic allergic airway disease.
We have previously shown that intranasal administration of an HDM extract (5 d/wk for 5 wk) elicits robust Th2-polarized airway inflammation and remodeling that is associated with increased airway hyperreactivity. Here, Balb/c mice were similarly exposed to HDM and concurrently treated with a pan-specific TGF-beta neutralizing antibody.
We observed that anti-TGF-beta treatment in the context of either continuous or intermittent HDM exposure had no effect on the development of HDM-induced airway remodeling. To further confirm these findings, we also subjected SMAD3 knockout mice to 5 weeks of HDM and observed that knockout mice developed airway remodeling to the same extent as HDM-exposed littermate controls. Notably, TGF-beta neutralization exacerbated the eosinophilic infiltrate and led to increased airway hyperreactivity.
Collectively, these data suggest that TGF-beta regulates HDM-induced chronic airway inflammation but not remodeling, and furthermore, caution against the use of therapeutic strategies aimed at interfering with TGF-beta activity in the treatment of this disease.
目前认为,慢性气道炎症和重塑均对过敏性哮喘的气道功能障碍和临床症状有显著影响。转化生长因子(TGF)-β是组织修复和炎症反应的有力调节因子,众多实验和临床研究表明,它可能在哮喘发病机制中起重要作用。
我们使用屋尘螨(HDM)诱导的慢性过敏性气道疾病小鼠模型,研究了TGF-β在调节过敏性气道炎症和重塑中的作用。
我们之前已表明,鼻内给予HDM提取物(每周5天,共5周)可引发强烈的Th2极化气道炎症和重塑,这与气道高反应性增加有关。在此,将Balb/c小鼠同样暴露于HDM,并同时用泛特异性TGF-β中和抗体进行治疗。
我们观察到,在持续或间歇性HDM暴露的情况下,抗TGF-β治疗对HDM诱导的气道重塑的发展没有影响。为进一步证实这些发现,我们还让SMAD3基因敲除小鼠接受5周的HDM暴露,并观察到基因敲除小鼠与暴露于HDM的同窝对照小鼠一样出现了气道重塑。值得注意的是,TGF-β中和加剧了嗜酸性粒细胞浸润,并导致气道高反应性增加。
总体而言,这些数据表明,TGF-β调节HDM诱导的慢性气道炎症,但不调节重塑,此外,在治疗该疾病时应谨慎使用旨在干扰TGF-β活性的治疗策略。